Mass. Biopharma Co. Launches IPO That Could Raise $120M
Clinical-stage biotech company Kaleido Biosciences launched an initial public offering Tuesday that could raise nearly $120.5 million if the offering is priced at the top of a projected range and if...To view the full article, register now.
Already a subscriber? Click here to view full article